Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
about
Stanniocalcin 2 is a negative modulator of store-operated calcium entrySurvival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas.STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma.Stanniocalcin 1 and ovarian tumorigenesis.STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro.Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients.Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinomaStanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling.Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targetsMicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2.Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer PatientsSTC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling.Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures.Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma.
P2860
Q28568485-1C26E5B7-391E-432F-AE65-C1A65CF40574Q33587519-D0B73D42-3C55-4BB3-A072-924468CB2BE6Q33670813-37123952-CD0F-45F5-BB56-356701DD9C98Q33888838-5E5AA03F-A0A5-4635-99D2-A46120B09616Q34049143-16F1A345-82D7-4B22-86E5-AE57AF8D5ABBQ34452789-0ADA9632-CA05-4BBA-A49B-143DDDCD7CFEQ35038659-10E063C9-305D-4AA7-98D8-8B9A4E4F172BQ35242102-E3028C53-2D4C-456D-9C42-0C9C63D4A6B7Q35652858-5CAB3899-B65B-4742-85BF-A680E66B093EQ36375091-8C2ED0FD-3AC9-48A3-9CBC-CA1A43C1BBF5Q36951387-54B73DD1-9DAF-412A-A9AE-CF5F1DD87277Q37701521-10BB66A4-A6C1-4E78-81BF-106D975A3CFAQ38804110-0FE2EC58-7696-4850-9373-7261F6EFFA5AQ39038772-69C2BE67-3E4F-42F3-B5E2-8F80B51D28C8Q42056870-F9DE9137-D667-46AD-BF39-FCC07AA3CB86
P2860
Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@en
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@nl
type
label
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@en
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@nl
prefLabel
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@en
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@nl
P2093
P2860
P1433
P1476
Stanniocalcin 2 overexpression ...... nd aggressive prostate cancer.
@en
P2093
Hidewaki Nakagawa
Hiroki Yoshioka
Kenji Tamura
Motohide Uemura
Mutsuo Furihata
Shingo Ashida
Su-Yong Chung
Taro Shuin
Tatsuo Iiyama
Tomoaki Fujioka
P2860
P304
P356
10.1111/J.1349-7006.2009.01117.X
P577
2009-02-26T00:00:00Z